13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • SPOTLIGHT

    Acronym: 

    SPOTLIGHT

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase III Tumour Stream Gastro-oesophageal
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Gastro-oesophageal
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase III, global multi-center, double-blind, randomised, efficacy study of IMAB362 plus mFOLOX6 compared with placebo plus mFOLOX6 as first-line treatment of subjects with Claudin (CLDN) 18.2 positive, HER2-Negative, metastatic gastric or gastroeophageal junction (GEJ) adenocarcinoma

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Sue Yeend Sue.Yeend@sa.gov.au 08 8222 6148 Tim Price Not Yet Recruiting